Analyst Update: Foamix Pharmaceuticals Ltd, Jazz Pharmaceuticals plc, and Healthways, Inc.

Analysts revised their ratings and price targets on Foamix Pharmaceuticals Ltd (FOMX), Jazz Pharmaceuticals plc – Ordinary Shares (JAZZ), and Healthways, Inc. (HWAY)

Aug 10, 2016 at 3:52 PM
facebook twitter linkedin

Analysts are weighing in on biopharmaceutical stocks Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) and Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ), as well as health management stock Healthways, Inc. (NASDAQ:HWAY). Here's a quick roundup of today's brokerage notes on FOMX, JAZZ, and HWAY.

  • FOMX was down more than 7% at its intraday low, after reporting a larger-than-expected per-share loss for the second quarter. However, the stock has since clawed to a 0.5% gain to sit at $8.18, and some analysts expect much more upside for FOMX. Specifically, Guggenheim raised its price target on FOMX to $20 from $10 -- in territory not charted -- and reiterated a "buy" endorsement. Since its most recent low at $5.70 in June, Foamix Pharmaceuticals Ltd shares have added nearly 44%, with pullbacks contained by its 20-day moving average. Short sellers have been keeping a close eye on FOMX, with short interest up 1.5% over the previous two reporting periods, now accounting for 8.8% of FOMX's float -- which would take almost two weeks of trading to cover, at FOMX's average daily volume. 
  • JAZZ is down 6.8% at $139.80 -- set for its worst session in five months -- after an earnings miss and and downwardly revised full-year forecast, though it's just one of several healthcare stocks swimming in red ink today. A handful of analysts have since issued price-target adjustments for JAZZ, including bumps from BMO and Leerink, to $193 and $202, respectively, as well as cuts from Mizuho and Goldman Sachs, to $185 and $195, respectively. Jazz Pharmaceuticals plc – Ordinary Shares is down 22.8% year-over-year, with the shares running into resistance in the $155-$160 region -- home to their 80-week moving average -- since April. Nevertheless, analysts are still upbeat on the stock, with all 11 brokerage firms weighing in calling JAZZ a "strong buy."
  • HWAY is up 18.8% at $21.45 -- and just off a new annual high of $22.76 -- after the company reported an earnings beat and announced that Robert E. Dries will take over the position of chief financial officer. Additionally, HWAY received price-target raises from Piper Jaffray (to $25.50), UBS (to $19), and Barrington (to $29). Thanks to today's pop, the stock is now up 67% year-to-date, and there's likely some bearish traders kicking rocks. Short interest on Healthways, Inc. jumped 5.2% in the latest reporting period, and now accounts for 9.3% of the stock's available float 
Don't miss the market's next move! Sign up now for Schaeffer's Midday Market Check

Special Offers from Schaeffer's Trading Partners